We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > DKN-01

News List

Leap Therapeutics announces orphan drug designation of DKN-01 for the treatment of gastric and gastroesophageal junction cancer pharmaceutical-business-review
June 17, 2020
Leap Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for DKN-01 for the treatment of gastric and gastroesophageal junction cancer.
BeiGene obtains certain rights for Leap Therapeutics’ cancer drug pharmaceutical-technology
January 07, 2020
Chinese biopharmaceutical firm BeiGene has agreed to exclusive rights to develop and commercialise Leap Therapeutics’ cancer drug DKN-01 in the Asia Pacific region, excluding Japan.
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing firstwordpharma
January 05, 2020
Raymond James & Associates, Inc. was the placement agent for the equity financing.
Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 americanpharmaceuticalreview
January 15, 2019
Leap Therapeutics announced an investigator-initiated study led by David R. Wise, M.D., Ph.D. of the Perlmutter Cancer Center at NYU Langone Health to study DKN-01......